S&P Global raises Endo ratings on Mallinckrodt merger completion

S&P Global Ratings upgraded Endo Inc. to 'BB-' from 'B+' and its debt instruments following its merger with Mallinckrodt PLC, subsequently withdrawing Endo's issuer credit rating as it is now considered a core subsidiary. While the merger moderately improves Mallinckrodt's business strength, S&P views the planned divestiture of the generics business as a slight credit negative due to reduced scale and increased product concentration, despite the remaining branded portfolio's better growth profile. The stable outlook reflects expectations for modest revenue growth and maintained debt leverage, though S&P highlights the absence of additional branded product pipeline assets as a key credit risk requiring future acquisitions.

Analysis

S&P Global Ratings has upgraded Endo Inc.'s corporate credit rating to 'BB-' from 'B+' following its merger with Mallinckrodt, reflecting its new status as a core subsidiary. This action included upgrades to Endo's specific debt instruments, with its super-priority facility reaching an investment-grade 'BBB-'. Despite the merger moderately improving Mallinckrodt's business strength, S&P views the subsequent strategic plan to divest the combined generics, API, and sterile injectables businesses as a slight credit negative. This spinoff, branded as Par Health, will reduce Mallinckrodt's scale to approximately $2 billion in revenue and significantly increase product concentration, with its top three products accounting for about 62% of sales. The negative impact of reduced scale and diversity is partly mitigated by the higher growth profile and superior EBITDA margins of the remaining branded business. This portfolio is anchored by Xiaflex and Acthar Gel, which are expected to grow, and the newly approved Terlivaz, which has a revenue potential of $200-$300 million before facing generic competition around 2029. A key credit risk identified by S&P is the absence of additional assets in the branded product pipeline, making future acquisitions essential for the company's long-term viability. The stable outlook is based on expectations of modest revenue growth and adjusted debt-to-EBITDA remaining between 2.5x and 3.5x over the next year.

Key Decisions for Investors

• Credit investors should note the split-rated nature of the post-merger debt, with the super-priority facility at 'BBB-' while the main corporate family remains speculative grade at 'BB-', reflecting differing recovery prospects.
• Equity investors must weigh the benefits of a higher-margin branded portfolio post-divestiture against the significant product concentration risk and the company's critical dependency on future acquisitions to replenish its weak pipeline.
• Closely monitor the execution of the Par Health spinoff and management's M&A strategy, as the ability to acquire new assets is deemed essential for long-term viability beyond the current 12-month stable outlook.
• The company's ability to maintain adjusted debt-to-EBITDA within the 2.5x to 3.5x range will be a crucial indicator of financial discipline and stability, and any deviation could trigger a re-evaluation of its credit profile.